HYPOLIPIDEMIC MEDICATIONS: CURRENT USE AND FUTURE PERSPECTIVES. PART 2. A COMMON APPROACHES FOR STATIN’S USING
Abstract
This article is devoted to discussion about main aspects of current use of 3-hydroxy-3-methylglutaril CoA reductase inhibitors (statins) according last international guidelines. Statin’s base effects on lipid profile, medication regimens, side effects and safety ensuring are represented.
About the Authors
A. E. Bagriy
Donetsk State Medical University
Russian Federation
Russian Federation
A. I. Dyadyk
Donetsk State Medical University
Russian Federation
Russian Federation
M. V. Khomenko
Donetsk State Medical University
Russian Federation
Russian Federation
I. N. Tsiba
Donetsk State Medical University
Russian Federation
Russian Federation
V. A. Efremenko
Donetsk State Medical University
Russian Federation
Russian Federation
E. V. Schukina
Donetsk State Medical University
Russian Federation
Russian Federation
O. A. Prikolota
Donetsk State Medical University
Russian Federation
Russian Federation
References
1. Сусеков А.В. Современные подходы в лечении дислипидемий: от научных дискуссий к конкретному больному // Медицинский Совет. 2015. № 12. С. 94-102.
2. Бритов А.Н., Поздняков Ю.М., Волкова Э.Г. и др. Национальные рекомендации по кардиоваскулярной профилактике // Кардиоваскулярная терапия и профилактика. 2011 № 10 (Приложение 2). 64 с.
3. Аронов Д.М., Арабидзе Г.Г., Ахмеджанов Н.М. и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации (V пересмотр). М., 2012. 50 с. [Электронный ресурс]: http://www.scardio. ru/content/Guidelines/rek_lipid_2012.pdf
4. Wright R. S., Murphy J. PROVE-IT to IMPROVE-IT Why LDL-C Goals Still Matter in Post-ACS Patients // J. Amer. Coll. Cardiol. 2016. Vol. 67, N 4. P.362-364.
5. Campos-Outcalt D. The new cardiovascular disease prevention guidelines: what you need to know // J. Fam. Pract. 2014. Vol. 63, N 2. P. 89-93.
6. Opie L.H., Gersh B.J. Drugs for the heart. - Philadelphia: Elsevier, 2013. - 592 p.
7. Кутищенко Н.П., Толпыгина С.Н., Лукина Ю.В. и др. Национальные рекомендации по эффективности и безопасности лекарственной терапии при первичной и вторичной профилактике сердечно-сосудистых заболеваний // Рационал. фармакотер. кардиол. 2011. Т.7, № 3 (Приложение). 72 с.
8. Bittner V. Selecting Patients for Statin Therapy in Primary Prevention If We Could Only Predict the Future // J. Amer. Coll. Cardiol. 2015. Vol. 65, N 21. P. 2710-2712.
9. Antman E.M., Jessup M. Clinical practice guidelines for chronic cardiovascular disorders: a roadmap for the future // J. Amer. Med. Ass. 2014. Vol. 311, N 12. P. 1195-1196.
10. Карпов Ю.А., Кухарчук В.В., Лякишев А.А. и др. Диагностика и лечение хронической ишемической болезни сердца. Клинические рекомендации МЗ России. М. 2013. 69 с. Электронный ресурс: http:// medi.ru/doc/a030923.htm
11. Drozda J. P., Ferguson Т. B., Jneid Hani et al. 2015 ACC/ AHA Focused Update of Secondary Prevention Lipid Performance Measures. A Report of the ACC/AHA // J. Amer. Coll. Cardiol. 2016. Vol. 67, N 5. P. 558-587.
12. Silva V.S., Martin L.C., Franko L.C. et al. Pleiotropic effects of statins may improve outcomes in atherosclerotic renovascular disease // Amer. J. Hypertens. 2008. Vol. 21, N 10. P. 1163-1168.
13. Jukema J.W., Cannon C.P., de Craen A.J.M. et al. The controversies of statin therapy. Weighing the evidence // J. Amer.Coll. Cardiol. 2012. Vol.60. P. 875-881.
14. Ramos R., Garc a-Gil M., Comas-Cuf M. et al. Statins for Prevention of Cardiovascular Events in a Low-Risk Population With Low Ankle Brachial Index // J. Amer. Coll. Cardiol. 2016. Vol.67. P. 630-640.
15. Reiner Z., Catapano A.L., De Baker G. et al. ESC/ EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) // Eur. Heart J. 2011. Vol. 32. P. 1769-1818.
16. Stone N.J. , Robinson J. , Lichtenstein A.H. et al. ACC/ AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults // J. Amer. Coll. Cardiol. 2014. Vol.63, N 25. P. 2889-2934.
17. Stone N.J., Lloyd-Jones D. M. Lowering LDL Cholesterol Is Good, but How and in Whom? // N. Engl. J. Med. 2015. Vol.372. P.1564-1565.
18. Eckel R.H., Jakicic J.M., Ard J.D. et al. AHA/ ACC Guideline on lifestyle management to reduce cardiovascular risk // Circulation. 2013. [Электронный ресурс]: http://circ.ahajournals.org/content/ early/2013/11/11/01.cir.0000437740.48606.d1. pdf
19. Jensen M.D., Ryan D.H., Apovian C.M. et al. AHA/ ACC/TOS Guideline for the management of overweight and obesity in adults // J. Amer. Coll. Cardiol. 2014. Vol.63, N 25. P. 2995-3023.
20. Weber M.A., Schiffrin E.L., White W.B. et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension // J. Clin. Hypertens. 2013. Режим доступа к журн.: http://www.ash-us.org/documents/ASH_ ISH-Guidelines_2013.pdf
21. Montalescot G. , Sechtem U. , Achenbach S. et al. Guidelines on the management of stable coronary artery disease // Eur. Heart J. 2013. Режим доступа к журн.: http://www.escardio.org/guidelines-surveys/ esc-guidelines/GuidelinesDocuments/2013_Stable_ Coronary_Artery_ Disease_web_addenda.pdf.
22. Jacobson T.A., Ito M.K., Maki K.C. et al. National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1 // J. Clin. Lipidol. 2014. Vol.8, N 6. P.554-561.
23. Jacobson T.A., Maki K.C., Orringer C.E. et al. National Lipid Association Recommendations for Patient- Centered Management of Dyslipidemia: Part 2 // J.Clin. Lipidol. 2015. Vol. 9, N 6 (Suppl.). P. S1-S122.
24. Murphy S. A., Cannon C. P., Giugliano R. et al. Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome The IMPROVE-IT Trial // J. Amer. Coll. Cardiol. 2016. Vol. 67. P. 353-361.
25. Giugliano R.P., Sabatine M.S. Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field? // J. Amer. Coll. Cardiol. 2015. Vol. 65, N 24. P. 2638-2651.
26. Parker B.A., Capizzi J.A., Grimaldi A.S. et al. Effect of statins on skeletal muscle function// Circulation. 2013. Vol.127. P. 96-103
27. Newman C., Tsai J., Szarek M. et al. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 complete trials in 14236 patients // Amer. J. Cardiol. 2006. Vol. 97, N 1. P. 61-67.
28. Nordestgaard B.G., Chapman M. J., Humphries S. E. et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Consensus Statement of the European Atherosclerosis Society // Eur. Heart J. 2013. Vol.34. P. 3478-3490.
29. Amsterdam E.A., Wenger N.K., Brindis R.G. et al. 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes: Executive Summary A Report of the ACC / AHA Task Force on Practice Guidelines // Circulation. 2014. Vol.130. P. e431-e432.
30. Ивашкин В. Т., Маевская М.В. Павлов Ч. С. и др. Диагностика и лечение неалкогольной жировой болезни печени / Под ред. акад. В. Т. Ивашкина. М. 2012. 27 с. Электронный ресурс: http://www.rsls.ru/ files/Guidelines-RSLS-NASH-2015-09-21.pdf
31. American Diabetes Association Standards of Medical Care in Diabetes-2016 // Diabetes Care. 2016. Vol. 39 (Suppl 1). 112 p. Режим доступа к журн.: http:// healthmonix.com/ADAWebcastSOC2016/common/files/ Clinical%20Diabetes%20abridged.pdf
32. Ruilope L. M. Long-term adherence to therapy: the clue to prevent hypertension consequences // Eur. Heart J. 2013. Vol. 34. Р. 2931-2932.
Review
For citations:
Bagriy A.E., Dyadyk A.I., Khomenko M.V., Tsiba I.N., Efremenko V.A., Schukina E.V., Prikolota O.A. HYPOLIPIDEMIC MEDICATIONS: CURRENT USE AND FUTURE PERSPECTIVES. PART 2. A COMMON APPROACHES FOR STATIN’S USING. Ateroscleroz. 2016;12(2):48-57. (In Russ.)
Views:
429
Email this article 